Cargando…

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumors

OBJECTIVES: Germ cell tumors are highly susceptible to chemotherapy; however, there is a lack of established treatments for consistently relapsing germ cell tumor. Therefore, in this phase II study, we evaluated the efficacy and safety of nivolumab for relapsed germ cell tumor. METHODS: Seventeen ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawahara, Takashi, Kawai, Koji, Kojima, Takahiro, Nagumo, Yoshiyuki, Sakka, Shotarou, Kandori, Shuya, Negoro, Hiromitsu, Mathis, Bryan J, Maruo, Kazushi, Miura, Koji, Sakamoto, Noriaki, Shinohara, Nobuo, Yamashita, Shinichi, Yonemori, Kan, Kishida, Takeshi, Ukimura, Osamu, Nishimura, Kazuo, Kobayashi, Yasuyuki, Nishiyama, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles: Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545636/ https://www.ncbi.nlm.nih.gov/pubmed/35462438 http://dx.doi.org/10.1111/iju.14885

Ejemplares similares

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
por: Isoda, Bunpei, et al.
Publicado: (2023)

Laparoendoscopic single‐site surgery for urachal remnant with extraperitoneal approach through a suprapubic port
por: Hoshi, Akio, et al.
Publicado: (2022)

Whole-Blood Gene Expression Profiles Correlate with Response to Immune Checkpoint Inhibitors in Patients with Metastatic Renal Cell Carcinoma
por: Nagumo, Yoshiyuki, et al.
Publicado: (2022)

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma
por: Hamada, Kazuki, et al.
Publicado: (2023)

ELOVL5‐mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma
por: Nitta, Satoshi, et al.
Publicado: (2022)

Glucocorticoids coordinate the bladder peripheral clock and diurnal micturition pattern in mice
por: Chihara, Ichiro, et al.
Publicado: (2023)

Case Report: Molecular Characterization of Aggressive Malignant Retroperitoneal Solitary Fibrous Tumor: A Case Study
por: Nonaka, Haruna, et al.
Publicado: (2021)

ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma
por: Tanaka, Ken, et al.
Publicado: (2022)

Retroperitoneal lymph node dissection for testicular cancer in a patient with a double inferior vena cava
por: Yamaguchi, Akane, et al.
Publicado: (2021)

Granulocyte colony‐stimulating factor associated arteritis in a patient with castration‐resistant prostate cancer
por: Nitta, Satoshi, et al.
Publicado: (2021)

Diffuse alveolar hemorrhage with nivolumab monotherapy
por: Shannon, Vickie R., et al.
Publicado: (2020)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer
por: Kawahara, Takashi, et al.
Publicado: (2019)

Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma
por: Grzegorczyk, Aleksandra, et al.
Publicado: (2023)

Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples
por: Kurobe, Masahiro, et al.
Publicado: (2016)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

Bmal1 Regulates Prostate Growth via Cell-Cycle Modulation
por: Ueda, Masakatsu, et al.
Publicado: (2022)

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
por: Hasegawa, Hirotaka, et al.
Publicado: (2022)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer
por: Nawashiro, Ayako, et al.
Publicado: (2022)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

Editorial Comment to Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
por: Kandori, Shuya
Publicado: (2020)

Underweight body mass index is a risk factor of mortality in outpatients with nocturia in Japan
por: Negoro, Hiromitsu, et al.
Publicado: (2015)

Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor
por: Kurobe, Masahiro, et al.
Publicado: (2014)

Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy
por: Inagaki, Chiaki, et al.
Publicado: (2023)

Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
por: Narukawa, Tsukasa, et al.
Publicado: (2020)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
por: Schwab, Katjana S., et al.
Publicado: (2019)

Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer
por: Inoue, Yusuke, et al.
Publicado: (2020)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
por: Glutsch, Valerie, et al.
Publicado: (2019)

Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
por: Watanabe, Hayato, et al.
Publicado: (2021)

Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

TRPV4-dependent induction of a novel mammalian cold-inducible protein SRSF5 as well as CIRP and RBM3
por: Fujita, Takanori, et al.
Publicado: (2017)

A case of renal involvement in juvenile xanthogranulomatosis
por: Shibuki, Saki, et al.
Publicado: (2022)

Clinical Impact of Prognostic Nutrition Index for Advanced Gastric Cancer Patients with Peritoneal Metastases Treated Nivolumab Monotherapy
por: Lee, Jungmin, et al.
Publicado: (2022)

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2023)

Risk analyses of nocturia on incident poor sleep and vice versa: the Nagahama study
por: Negoro, Hiromitsu, et al.
Publicado: (2023)

Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma
por: Morita, Akimichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_060av955knvq37ulombs651jiq